Venous thromboembolism in Wegener's granulomatosis.

Peter Lamprecht, Konstanze Holl-Ulrich and Stefan Wieczorek

J Rheumatol 2007;34;2323-2325
http://www.jrheum.org/content/34/12/2323.citation

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Venous Thromboembolism in Wegener’s Granulomatosis

Wegener’s granulomatosis (WG) is a potentially organ- or life-threatening, chronic inflammatory and autoimmune disease of unknown etiology characterized by necrotizing granulomatous lesions, glomerulonephritis, and an autoimmune vasculitis predominantly affecting small vessels, i.e., arterioles, capillaries, and venules. WG usually starts as granulomatous disease of the respiratory tract (so-called localized) before it converts to a systemic disease (generalized) in most patients with the emergence of antineutrophil cytoplasmic autoantibodies specific for “Wegener’s autoantigen” proteinase 3 (PR3-ANCA) and PR3-ANCA associated vasculitis1.

In vitro studies support the concept that PR3-ANCA interact with neutrophil granulocytes, causing premature intravascular neutrophil activation and degranulation, with subsequent endothelial damage and further leukocyte recruitment to the site of vasculitis2. Moreover, murine PR3-ANCA generated in PR3/elastase-deficient mice induce panniculitis in vivo upon passive transfer into mice challenged with intradermal tumor necrosis factor-α injection. Stronger pulmonary and renal inflammation is seen in lipopolysaccharide-primed mice in the presence of PR3-ANCA in this model3. Yet it remains unresolved how the immune response to PR3 is induced and sustained.

Danger-associated molecular patterns (DAMP) such as monosodium urate crystals induce dendritic cell maturation, antigen presentation, T cell activation, and cytokine production4,5. Intriguingly, PR3 also induces dendritic cell maturation in vitro via the protease-activated receptor-2 and evokes a stronger Th1-type T cell response in WG as compared to healthy and disease controls6. In many animal models break in tolerance and organ-specific autoimmunity is induced in the presence of a “proinflammatory environment” and sustained by neoformation of lymphoid-like structures in inflamed target organs7. WG-granulomata contain clusters of PR3+ cells (neutrophils/monocytes) surrounded by antigen-presenting cells, Th1-type CD4+CD28– effector memory T cells, and maturing B cells and plasma cells suggestive of lymphoid-like tissue neoformation8. Thus, in many respects the immune response to PR3 in WG resembles an uncontrolled response to DAMP.

To date, there have been few reports on venous thromboembolism (VTE) in WG9-11. A high incidence of VTE in WG (7.0 per 100 person-years; 95% CI 4.0 to 11.4) has been reported in a large prospective study (WeCLOT) recently12.

In this issue of The Journal, Sebastian, et al13 report on a prospective analysis of 3 rather common gene variations associated with hypercoagulability and VTE [factor V Leiden; G20210A mutation of prothrombin (factor II) gene; C677T mutation of methylenetetrahydrofolate reductase gene], anti-cardiolipin antibodies (aCL), and anti-ß2-glycoprotein I (anti-ß2-GPI) antibodies in 180 WG patients from the aforementioned study. The authors identified an increased frequency of low-titer aCL in WG. However, this finding as well as the presence of anti-ß2-GPI antibodies did not correlate with thrombotic events. Moreover, the prevalence of the 3 mutations associated with hypercoagulability was comparable to the rate in the general population. The study emphasizes findings from earlier reports on lack of association of aCL and anti-ß2-GPI antibodies with VTE in WG and excludes a specific role of the 3 common mutations for hypercoagulability and VTE in WG13. Statistical caveats include lack of power calculations to ensure cohort sizes and frequencies of the genetic exchanges to allow identification of significant differences between the cohorts. Further, aCL and anti-ß2-GPI were not detected in close temporal relation to VTE and serial assessment of ACL and anti-ß2-GPI titers was not pursued.

The study by Sebastian, et al13 raises a question: Which factors other than ACL, anti-ß2-GPI, and the 3 common gene mutations associated with hypercoagulability could cause VTE in WG? The number of factors influencing coagulability is large (Table 1)14. Weidner, et al11 excluded the following: deficiencies in proteins S and C, antiphospholipid antibodies, factor V Leiden, malignancy, surgery or trauma, pregnancy, oral contraceptives, hormone replacement therapy, immobilization, obesity, and smoking — as causes of VTE in a series of 13 patients [8 PR3-ANCA+ WG, 1 PR3-ANCA+ microscopic polyangiitis (MPA), 2 myeloperoxidase (MPO)–ANCA+ MPA, and 2 PR3-ANCA+ renal-limited vasculitides] from a cohort of 105 patients with ANCA-associated vasculitis. Another study also failed to identify hereditable or

See Frequency of aCL and genetic mutations associated with hypercoagulability in WG patients with and without history of thrombotic event, page 2446
acquired hypercoagulability factors apart from factor V Leiden mutation in heterozygous state in one of 5 pediatric patients with WG\(^\text{10}\). Intriguingly, VTE was observed in 2 WG patients and 1 patient with MPA and reactivated cytomegalovirus (CMV) infection. Whereas VTE is uncommon in CMV infection, e.g., after organ transplantation, the combined effects of endothelial CMV infection and vasculitis might facilitate VTE in WG and MPA\(^\text{9}\). So far, the influence of CMV infection on VTE and other manifestations has not been analyzed in greater detail in WG. Moreover, the effects of genetic risk factors for WG such as HLA-DPB1*0401 and PTPN22*620W on VTE in WG have not yet been evaluated\(^\text{15}\).

Most VTE episodes reported in ANCA-associated vasculitides occurred during active disease. Moreover, VTE is seen in PR3–ANCA+ WG more frequently than in MPO–ANCA+ MPA, even when you consider that WG has a higher incidence and prevalence compared with MPA\(^\text{10-12}\). Of note, “Wegener’s autoantigen” PR3 and PR3-ANCA, but not MPO, induce endothelial tissue factor (TF) \textit{in vitro}. Endothelial TF initiates blood coagulation by the interaction with factor VII, resulting in the subsequent generation of thrombin\(^\text{16,17}\). Further, antibodies to complementary PR3 (cPR3), synthesized from the antisense/noncoding strand of the PR3 gene, are detected in a subset of PR3–ANCA+ WG patients\(^\text{18}\). Recently, anti-cPR3 antibodies were reported to interact with plasminogen\(^\text{19}\).

Assuming that endothelial damage in active disease may be causally linked to VTE in WG, one might expect morphological signs of active phlebitis in patients with WG and VTE. However, studies demonstrating active phlebitis as a possible origin of VTE in WG are lacking. Although it is well known that ANCA-associated vasculitis can affect large vessels of both arterial and venous type, studies dealing with morphological analysis of medium and large-vessel involvement in

---

**Table 1. Inherited and acquired causes of venous thrombosis.**

<table>
<thead>
<tr>
<th>Inherited</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Common</td>
<td></td>
</tr>
<tr>
<td>G1691A mutation in the factor V gene (factor V Leiden)</td>
<td></td>
</tr>
<tr>
<td>G20210A mutation in the prothrombin (factor II) gene</td>
<td></td>
</tr>
<tr>
<td>Homozygous C677T mutation in the methylenetetrahydrofolate reductase gene</td>
<td></td>
</tr>
<tr>
<td>Rare</td>
<td></td>
</tr>
<tr>
<td>Antithrombin deficiency</td>
<td></td>
</tr>
<tr>
<td>Protein C deficiency</td>
<td></td>
</tr>
<tr>
<td>Protein S deficiency</td>
<td></td>
</tr>
<tr>
<td>Very rare</td>
<td></td>
</tr>
<tr>
<td>Dysfibrinogenemia</td>
<td></td>
</tr>
<tr>
<td>Homocysteinuria in homozygous state</td>
<td></td>
</tr>
<tr>
<td>Probably inherited</td>
<td></td>
</tr>
<tr>
<td>Increased levels of factor VIII, Factor XI, Factor XI, or fibrinogen (not attributable to inflammation)</td>
<td></td>
</tr>
</tbody>
</table>

**Acquired**

| Surgery and trauma |  |
| Prolonged immobilization |  |
| Older age |  |
| Obesity |  |
| Nephrotic syndrome |  |
| Smoking |  |
| Cancer |  |
| Inflammation |  |
| Myeloproliferative disorders |  |
| Pregnancy and puerperium |  |
| Use of contraceptives or hormone replacement therapy |  |
| Mild to moderate hyperhomocysteinemia |  |
| Antiphospholipid antibodies |  |

From Seligson U, Lubetsky A. N Engl J Med 2001; 344:1222-31; adapted with permission\(^\text{14}\).

---

**Figure 1.** A. Venous thrombosis of the lower limb in a patient with WG: medium-size vein with fresh thrombus (right), but with no sign of phlebitis (H&E, original magnification \(\times 25\)). B. Same patient as in A: pulmonary embolism (stars) in medium-size pulmonary artery with beginning organization of thromboembolus, covered with endothelia. No vasculitis is noted (H&E, \(\times 100\)). C. Venulitis (V) in active WG of sinu-nasal mucosa showing prominent endothelia and subendothelial fibrinoid necrosis in a dense mixed inflammatory background (H&E, original magnification \(\times 100\)).
WG have mainly focused on the arterial side.20. Whereas venulitis is a well known phenomenon of active ANCA-associated vasculitis {Figure 1C}, phlebitis of medium and large-size peripheral veins has not been convincingly demonstrated. Indeed, in our own cohort of 4 autopsy cases of VTE in WG patients, none of the affected vessels showed active phlebitis {Figure 1A and 1B}. It remains to be determined how the above mentioned uncontrolled immune response, PR3, PR3-ANCA, and/or anti-cPR3 antibodies are involved in the pathogenesis of venulitis and glomerular capillary thrombosis typical of WG, and how they might give rise to the involvement of medium to large-size veins and VTE in some patients with WG. Further analysis of the impact of these and other factors on VTE in WG may yield even more promising data.

PETER LAMPRECHT, MD,
Department of Rheumatology,
Vasculitis Center UKSH,
University of Lübeck,
and Rheumaklinik Bad Bramstedt;

KONSTANZE HOLL-ULRICH, MD,
Institute for Pathology,
University of Lübeck,
Lübeck;

STEFAN WIECZOREK, MD,
Department of Human Genetics,
Ruhr-University,
Bochum, Germany

Supported by grants from the German Research Society (Deutsche Forschungsgemeinschaft/DFG: La1339 and KFO170), Innovationsfonds Schleswig-Holstein, and Verein zur Förderung der Erforschung und Bekämpfung rheumatischer Erkrankungen Bad Bramstedt e.V. Address reprint requests to Dr. P. Lamprecht, Ratzeburger Allee 160, 23538 Lübeck, Germany. E-mail: lamprecht@rheuma-zentrum.de

REFERENCES

Lamprecht, et al: Editorial

Downloaded from www.jrheum.org on September 7, 2017 - Published by The Journal of Rheumatology

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2007. All rights reserved.